Changes of cardiovascular biomarkers and antioxidants during sedation by xylazine, detomidine, medetomidine, and dexmedetomidine in goats

Author(s):  
Amir Saeed Samimi ◽  
Mohammad Mahdi molaei ◽  
Omid Azari ◽  
Hossein Mashayekhi ◽  
Farshid Akbarpour
2020 ◽  
Vol 18 ◽  
Author(s):  
Zlatko Fras ◽  
Dimitri P. Mikhailidis

: In this second part of a review of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), we discuss the findings in relation to patients with stroke, the ACS phenotype, history of coronary artery bypass graft surgery, heart failure, concurrent polyvascular atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus, and different levels of expression of selected cardiovascular biomarkers. The combination therapy was proven safe, and drug discontinuation rates were not increased by adding ezetimibe. Since both statins and ezetimibe are now almost globally generically available, we can conclude that for secondary prevention of ASCVD, adding ezetimibe to high-intensity statin therapy further reduces low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk cost-effectively.


2021 ◽  
Vol 141 (5) ◽  
pp. S122
Author(s):  
K. Navrazhina ◽  
Y. Renert-Yuval ◽  
J. Frew ◽  
D. Grand ◽  
S. Garcet ◽  
...  

2021 ◽  
pp. 101401
Author(s):  
Sylvia E. Badon ◽  
Nerissa Nance ◽  
Renee Fogelberg ◽  
Charles Quesenberry ◽  
Monique M. Hedderson ◽  
...  

2012 ◽  
Vol 10 (8) ◽  
pp. 989-994 ◽  
Author(s):  
Therese M Heinonen ◽  
Maira Aamer ◽  
Cameron Marshall ◽  
Donald M Black ◽  
Jean-Claude Tardif

2018 ◽  
Vol 14 (11) ◽  
pp. S11
Author(s):  
Deepak L Bhatt ◽  
Sangeeta Kashyap ◽  
Philip R Schauer ◽  
Ali Aminian ◽  
John P Kirwan ◽  
...  

Biomarkers ◽  
2010 ◽  
Vol 15 (5) ◽  
pp. 454-460 ◽  
Author(s):  
Yui Sekitani ◽  
Naomi Hayashida ◽  
Koichiro Kadota ◽  
Hironori Yamasaki ◽  
Norio Abiru ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document